COMBINATION OF WEEKLY RADIATION AND DOCETAXEL FOR LOCALLY ADVANCED NON SMALL CA

每周放疗和多西紫杉醇相结合治疗局部晚期非小 CA

• 批准号: 7376351
• 负责人: PAUL O SCHWARZENBERGER
• 金额: $ 0.02万
• 依托单位: TULANE UNIVERSITY OF LOUISIANA
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376351
• 关键词: COMBINATION; WEEKLY; RADIATION; DOCETAXEL; LOCALLY

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Locally advanced or unresectable non-small cell lung cancer (NSCLC) is considered an incurable disease with a life expectancy of less than two years regardless of treatment. Many patients with stage II and most with stage III NSCLC are initially controlled with surgery or radiation relapse at a remote site. This is believed to be due to the presence of malignant cells within the local tumor draining lymphatic system or at remote sites at the time of initial diagnosis. Local treatment modalities such as tumor irradiation as well as systemic chemotherapy have been clearly ineffective in controlling disease progression. Until recently, the benefit of treating locally advanced NSCLC has been controversial since some studies did not show improved survival over no treatment at all. Nevertheless, treatment was offered due to improved quality of life associated with treatment. Chemotherapy, radiation or both in succession are presently offered by most oncologist to these patients. It was hypothesized that both systemic and locoregional control of the disease could be improved by combining radiation and chemotherapy, subsequentially or concomitantly. This study aims to investigate if the combination of the drug Taxotere given one day before radiation is well tolerated and will result in enhanced shrinkage of the cancer as compared to traditional radiation therap

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。局部晚期或不可切除的非小细胞肺癌（NSCLC）被认为是一种无法治愈的疾病，无论治疗方法如何，预期寿命都不到两年。许多II期和大多数III期NSCLC患者最初通过手术或放射治疗在远处复发得到控制。这被认为是由于在最初诊断时，在局部肿瘤引流淋巴系统或远处部位存在恶性细胞。局部治疗方式，如肿瘤照射和全身化疗在控制疾病进展方面显然无效。直到最近，治疗局部晚期NSCLC的益处一直存在争议，因为一些研究并没有显示比不治疗更能提高生存率。然而，由于与治疗相关的生活质量改善，治疗得以提供。目前大多数肿瘤学家为这些患者提供化疗、放疗或两者兼而有之。据推测，通过放疗和化疗的联合治疗，无论是随后的还是同时的，都可以改善疾病的全身和局部控制。这项研究的目的是调查放射治疗前一天给予Taxotere药物是否具有良好的耐受性，并且与传统的放射治疗相比，是否会导致癌症的缩小